澳大利亚正掀起女性冻卵的热潮,越来越多女性出于非医学原因选择这一方式来保存生育能力。1美国的数据反映了这一全球趋势——2014年至2021年间,计划性冻卵周期从4,153个增加至16,436个。1然而,数据也显示出现实与期待之间的落差:在2014年至2016年期间冻卵的女性中,仅有5.7%在五至七年内返回使用卵子。1
冻卵的高昂成本是女性面临的重要考量。1澳大利亚每个周期的冻卵费用通常为8,000至12,000澳元,此外还需支付年度存储费。1冻卵之所以在澳大利亚获得关注,与国内辅助生殖技术的发展息息相关。2024年澳大利亚进行了超过113,000个IVF治疗周期,产生了超过20,900名婴儿,其中四分之三通过冻胚胎出生。1与此同时,抗苗勒激素(AMH)测试在澳大利亚2011年至2021年间增长了13倍,30至34岁女性的这项检测增长幅度更是接近20倍,这表明更多女性在评估自身生育能力。1
为应对辅助生殖技术的快速发展,澳大利亚政府已启动改革。2024年9月,卫生部长要求对该领域进行审查,2025年9月发布了10项改革建议,相关过渡方案预计在2028年12月前完成。1
An increasing number of women in Australia are opting to freeze their eggs for non-medical reasons, seeking to preserve their reproductive capacity for future use. In the United States, the trend has been particularly pronounced, with elective egg freezing cycles rising from 4,153 in 2014 to 16,436 by 2021 1. However, the data reveals a significant gap between intention and action: among women who froze eggs between 2014 and 2016, only 5.7% returned to use their frozen eggs within five to seven years 1.
The financial commitment required for egg freezing in Australia remains substantial, with a single cycle typically costing between 8,000 and 12,000 Australian dollars, plus annual storage fees 1. Despite these expenses, the procedure continues to gain traction as a fertility insurance measure. In Australia, more than 113,000 IVF treatment cycles were conducted in 2024, resulting in over 20,900 babies, with three-quarters of these IVF births involving frozen embryos 1. Growing awareness of fertility options is also reflected in medical testing patterns, with anti-Müllerian hormone (AMH) tests in Australia increasing thirteenfold between 2011 and 2021, and nearly twentyfold among women aged 30 to 34 1.
The regulatory landscape is undergoing significant reform. In September 2024, the health minister called for a comprehensive review of assisted reproductive technology practices 1. Following this review, ten reform recommendations were released in September 2025, with transition measures expected to be completed by December 2028 1.
评论
还没有评论,欢迎留下第一条。